An independent two-stage DCF analysis by a frontier AI model.
Moderna is currently navigating a significant transition period. Following the initial success of its mRNA vaccines, the company is now focused on demonstrating the broader applicability and commercial viability of its mRNA technology platform across various therapeutic areas. This transition is characterized by current negative free cash flow as the company invests heavily in its extensive pipeline.
The intrinsic value of the company is heavily dependent on the successful execution of these future clinical and commercial milestones. Until a clearer picture emerges regarding the timeline and magnitude of positive cash flows from new products, establishing a precise intrinsic value remains challenging, leading to a cautious, fair value assessment based on the available data.
Assuming a normalized FCF of $2B based on its pipeline potential and past profitability, a 5% growth rate reflects the gradual commercialization of new mRNA therapies, discounting the current transitional negative FCF.
A higher 9% discount rate accounts for the elevated risk profile during the company's pipeline transition and reliance on future clinical trial outcomes.
A 3% terminal growth rate assumes the long-term viability and broader application of the mRNA technology platform across various therapeutic areas.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $121.54 | $101.28 | $86.81 | $75.96 | $67.52 |
| 2.5% | $135.04 | $110.49 | $93.49 | $81.02 | $71.49 |
| 3.0% | $151.92 | $121.54 | $101.28 | $86.81 | $75.96 |
| 3.5% | $173.62 | $135.04 | $110.49 | $93.49 | $81.02 |
| 4.0% | $202.56 | $151.92 | $121.54 | $101.28 | $86.81 |
■ Undervalued vs current price ■ Overvalued vs current price
Due to the company's current negative free cash flow and the uncertain timing of future pipeline commercialization, reliable specific growth rates cannot be verified and are therefore omitted.
The verdict reflects the transitional state of the company, balancing its proven mRNA technology platform against the current lack of positive cash generation and reliance on future pipeline success.
The significant negative free cash flow (-1.33B) highlights the current investment phase, making traditional DCF models difficult to apply without speculative assumptions, which this analysis avoids.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.